Loading
A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01875393 by Steba Biotech S.A., with 81 participants recorded, started 2013-05 and reaching its primary completion in 2014-12. Interventions recorded: TOOKAD® Soluble. Conditions recorded: Prostate Cancer.
Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.